CD47 and neoplasm: Antibodies blocking the CD47-SIRPα interaction increased phagocytosis of macrophages (22, 23) and cytotoxicity of PMNs (12), inhibited tumor engraftment (22), and eliminated pre-existing tumors in mice (24).